FDA approves Novartis drug Kisqali for further indication of dpa-AFX

BASEL (dpa-AFX) – The US Health Care FDA hat tie Novartis (SIX:) -Medikament Kisqali for the treatment of patients with a bestimmten form of Brustkrebs in Frühstadium-zugelassen. Das Unternehmen teilte dies in de Dienstagabend mit.

The disease is seen as patients with hormonal receptor-positive, HER2-negative Brustkrebs in Stage II and III, who have a high risk of relapse. Laut Studien could Kisqali in Combination with a hormone therapy of the relapse in the story of all hormone therapies on 25 days ago. If it is useful to do something, the Krebs can no longer work.

Kisqali has the responsibility of the company relations on the treatment of fortgeschrittenem Brustkrebs-zugelassen and finds them in Europe in the Prüfung for the Zulassung in the Frühfase of the Erkrankung. If the care for the care is provided when the patient becomes ill, a treatment with such a CDK4/6-hemmer with Kisqali infringement will come.